Printivo is a cutting-edge brand in the field of biomedical science, specializing in 3D-bioprinting. Their mission is to push the boundaries of technological advances to achieve human immortality. Printivo focuses on designing 3D human bone tissue for in-vitro efficacy and toxicity assays, providing pharmaceutical companies with bone tissue graft on demand for drug testing in pre-clinical trials.

Printivo utilizes their own 3D-bioprinting pneumatic extrusion technology, with their bioprinter EVE perfectly complementing their bioink formulas. They place a strong emphasis on tissue engineering, creating and optimizing the microarchitecture of their tissue constructs to mimic native conditions. Printivo also works with various cell lines, including stem cells, differentiating and studying their protein production and activity.

Their accolades include being the winners of the Accelerator Startup Sofia and the CIDIC Award, as well as being finalists in Betapitch Global and CESAwards. With a team of highly educated and experienced professionals in medicine, biotechnologies, and engineering, including founder and CEO Spas Kerimov, MD, and founder and CTO Radostin Stefanov, Printivo is dedicated to providing accurate and sophisticated data to bridge the gap between pre-clinical and clinical phases of the drug development value chain